Exosome Diagnostics
Sylvester Comprehensive Cancer Center Wins $2.5M NCI Grant to Develop Prostate Cancer Test
The team will work with collaborators at Bio-Techne's Exosome Diagnostics to develop its prostate cancer biomarker on a new platform.
The new data found that patients identified as low risk by the test received fewer biopsies and were less likely to be diagnosed later with high-grade prostate cancer.
Thermo Fisher Scientific Deal Expands Possibilities for Exosome Dx Business, Bio-Techne CEO Says
Premium
The deal with Thermo Fisher is for the development of Bio-Techne's second test in its Exosome Diagnostics portfolio, a multigene assay for kidney transplant rejection.
Bio-Techne Obtains Reimbursement Contract With Humana for Exosome Diagnostics Prostate Biopsy Test
Bio-Techne's CEO said the coverage decision will expand access to its EPI test and enable additional men to better decide whether to proceed with a prostate biopsy.
Qiagen, Exosome Dx Building Urine-Based Digital PCR Workflow for FGFR Mutations in Bladder Cancer
Premium
The firms will present a clinical comparison study using the workflow to detect FGFR mutations in 50 urothelial cancer patients later this year.